We are live on ! Find out more
AMBI

Ambit Biosciences Corp
AMBI

Delisted

AMBI was delisted on the 10th of November, 2014.

23 hedge funds and large institutions have $76M invested in Ambit Biosciences Corp in 2013 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 6

106% more capital invested

Capital invested by funds: $36.9M → $76M (+$39.1M)

53% more funds holding

Funds holding: 1523 (+8)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

Holders
23
Holders Change
+8
Holders Change %
+53.33%
% of All Funds
0.75%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
15
Increased
1
Reduced
3
Closed
6
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
O
1
OrbiMed
New York
$23.1M
GPP
2
Great Point Partners
Connecticut
$13.7M +$11.7M +883,459 New
Fidelity Investments
3
Fidelity Investments
Massachusetts
$12.4M
BBA
4
Baker Bros. Advisors
New York
$11.6M
WC
5
Wexford Capital
Florida
$9.27M -$321K -24,200 -4%
Millennium Management
6
Millennium Management
New York
$1.56M +$1.34M +100,810 New
EI
7
EAM Investors
California
$1.54M +$1.32M +99,447 New
Vanguard Group
8
Vanguard Group
Pennsylvania
$604K +$517K +38,981 New
Morgan Stanley
9
Morgan Stanley
New York
$498K +$96.4K +7,271 +29%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$401K +$343K +25,868 New
SIM
11
Spark Investment Management
New York
$378K +$321K +24,200 New
Northern Trust
12
Northern Trust
Illinois
$231K +$198K +14,916 New
Bank of New York Mellon
13
Bank of New York Mellon
New York
$195K +$167K +12,600 New
FM
14
Forward Management
California
$177K -$429K -32,385 -57%
BIT
15
BlackRock Institutional Trust
California
$147K +$126K +9,491 New
BG
16
BlackRock Group
United Kingdom
$42K +$35.6K +2,682 New
GH
17
GAM Holding
Switzerland
$25K +$21.8K +1,643 New
TRCT
18
Tower Research Capital (TRC)
New York
$19K -$38.8K -2,925 -71%
BA
19
BlackRock Advisors
Delaware
$18K +$15.6K +1,173 New
BJ
20
BlackRock Japan
Japan
$14K +$11.7K +879 New
U
21
UBS
Switzerland
$5K +$4.67K +352 New
AllianceBernstein
22
AllianceBernstein
Tennessee
$2K +$1.91K +144 New
JP Morgan Chase
23
JP Morgan Chase
New York
-$1.53M -218,300 Closed
PRCM
24
Pine River Capital Management
Minnesota
-$1.22M -174,100 Closed
Alyeska Investment Group
25
Alyeska Investment Group
Illinois
-$525K -74,989 Closed

AMBI Hedge Fund Activity: Q3 2013 in Review

23 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Ambit Biosciences Corp (AMBI) for Q3 2013, worth a combined $76M — up 106% from $36.9M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new AMBI positions and 6 closed out — a net gain of 9 holders — while 1 added to existing stakes and 3 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $1.34M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $1.53M sold.

  • 23 institutional investors held Ambit Biosciences Corp (AMBI) as of Q3 2013, up from 15 in Q2 2013.
  • Funds reported $76M of Ambit Biosciences Corp stock for Q3 2013, up 106% quarter-over-quarter.
  • 15 funds opened new Ambit Biosciences Corp positions in Q3 2013 and 6 closed out, a net change of +9 holders.
  • The largest Ambit Biosciences Corp buyer in Q3 2013 was Millennium Management, an estimated $1.34M added.
  • The largest Ambit Biosciences Corp seller in Q3 2013 was JP Morgan Chase, an estimated $1.53M sold.

Based on aggregated 13F filings for Q3 2013.